Drug combination could set norms for advanced kidney cancer treatment
Category: #health  By Paroma Bhattacharya  Date: 2019-02-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Drug combination could set norms for advanced kidney cancer treatment

Reporting the results from a phase 3 clinical trial, an investigator from Dana-Farber Cancer Institute revealed that the combination of two drugs could be a first-line, new standard treatment for patients that are suffering from metastatic kidney cancer.

Sources familiar with the matter cited that patients who received the targeted agent axitinib, along with avelumab, an immunotherapy drug, had a considerable advantage in progression-free survival in comparison to those that received a targeted drug sunitinib (Sutent). Sunitinib supposedly has been a standard treatment for the most common form of kidney cancer- advanced clear cell renal cell carcinoma.

Lank Center’s Director for Genitourinary Oncology at Dana-Farber and senior and co-corresponding author of the JAVELIN Renal 101 trial report in the New England Journal of Medicine (NEJM), Toni K. Choueiri, MD, mentioned that the patients who received the drug combination had a higher response rate, which means their tumors shrank, in comparison to those who received only sunitinib.

Sources added that although the progression-free survival was enhanced with the combination treatment, added follow-ups are required for showing if the two-drug therapy expands to overall survival in comparison with the standard regimen.

Choueiri said that the drug combination is certainly better than sunitinib, which would hopefully lead to the U.S. FDA approval soon. The analysis apparently revealed that all the subgroups – poor-risk, intermediate, and good patient – benefitted from the combination treatment.

Choueiri has recently given an oral presentation on the same topic at the 2019 Genitourinary Cancers Symposium in San Francisco. Those results were concurrently published in the New England Journal of Medicine.

Choueiri further said that the combination is an important option for patients with advanced disease. The contributions made in the advanced kidney cancers is further pushing the envelope and the treatments might not be curative; however, patients are living longer, and the disease is becoming more chronic.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...

ViiV Healthcare announces positive result in TANGO Phase 3 study
ViiV Healthcare announces positive result in TANGO Phase 3 study
By Paroma Bhattacharya

ViiV Healthcare Limited, a pharmaceutical company specializing in HIV treatment, recently announced positive results from Phase 3 TANGO study.

The study was conducted to assess vira...

Skyhawk Therapeutics expands licensing partnership with Biogen
Skyhawk Therapeutics expands licensing partnership with Biogen
By Paroma Bhattacharya

Skyhawk Therapeutics, Inc. has recently announced the expansion of its partnership with Biogen, which was initially announced on January 4, 2019.

The expansion, which leverages on the breadth of SkySTAR™ technology platform from Skyh...